Ridgeline Therapeutics, Inc.
Publicly observedHouston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Houston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Ridgeline Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KM9RHDLMHTN5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant23 Sept 2026Publicly observed
NIH SBIR/STTR award: Cardiovascular Safety and Scalable Manufacturing for Investigational New Drug Filing of a Novel Oral Drug to Accelerate Musculoskeletal Recovery in Older Adults
USD 2,117,233.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults
USD 904,811.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults
USD 1,339,717.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.